NOBLE METAL COATED CENTRAL VENOUS CATHETERS ARE NOT SUPERIOR TO UNCOATED CATHETERS IN PREVENTING INFECTIOUS AND NON-INFECTIOUS COMPLICATIONS IN IMMUNOCOMPROMISED PATIENTS

Authors

  • Raheel Iftikhar Armed Forces bone marrow transplant centre
  • Qamar Un Nisa Chaudhry Armed Forces bone marrow transplant centre
  • Tariq Mehmood Satti Armed Forces bone marrow transplant centre
  • Syed Kamran Mahmood Armed Forces bone marrow transplant centre
  • Humayun Shafique Satti Armed Forces bone marrow transplant centre
  • Tariq Ghafoor Armed Forces bone marrow transplant centre
  • Mehreen Aali Khan Armed Forces bone marrow transplant centre

Abstract

Background: Patients with haematological malignancies and stem cell transplant recipients are at high risk of opportunistic infections. Little international and no national data is available comparing noble metal coated versus uncoated central venous catheters (CVC) in this special population of severely immunocompromised patients. Objective of the study is to compare infectious and non-infectious complications of noble metal coated versus uncoated central venous catheters in patients undergoing stem cell transplantation and receiving chemotherapy for acute myeloid leukaemia. Methods: This is a prospective, cross-sectional, randomized study (January to December 2016), enrolling 45 consecutive patients undergoing stem cell transplantation or chemotherapy for acute myeloid leukaemia. Patients were randomized in 2 groups. Twenty 23 patients received standard CVC and 22 patients received CVC catheters coated with three noble metals (Gold, Silver, Palladium). Patients were observed for catheter related infectious and non-infectious complications. Data was analysed using SPSS. Results: Mean age was 24.3 (±4.91) in uncoated and 25.09 (±5.22) in coated CVL group. CRBSI infection was detected in 2 (8.6%) and 3 (13.6%) patients in uncoated and coated group respectively with p value of .279. There was no statistically significant difference in febrile episodes between coated (95.4%) and uncoated (91.3%) group. While we considered non-infectious complications, 2 patients in coated (8.6%) and 1 in uncoated CVCs group (4.3%) had CVC thrombosis which was not significant statistically. Conclusion: There was no efficacy of BG-thin noble metal coated CVCs in reducing infectious and non-infectious complications (thrombosis) in our studyKeywords: Central Venous Catheters; Infection; thrombosis

Author Biographies

Raheel Iftikhar, Armed Forces bone marrow transplant centre

stem cell transplantation

Qamar Un Nisa Chaudhry, Armed Forces bone marrow transplant centre

stem cell transplaqnt

Tariq Mehmood Satti, Armed Forces bone marrow transplant centre

Stem Cell trasnplant

Syed Kamran Mahmood, Armed Forces bone marrow transplant centre

Stem Cell trasnplant

Humayun Shafique Satti, Armed Forces bone marrow transplant centre

stem cell transplant

Tariq Ghafoor, Armed Forces bone marrow transplant centre

stem cell transplant

Mehreen Aali Khan, Armed Forces bone marrow transplant centre

stem cell transplant

References

Dudeck MA, Edwards JR, Allen-Bridson K, GROSS C, Malpiedi PJ, Peterson KD, et al. National Healthcare Safety Network report, data summary for 2013, Device-associated Module. Am J Infect Control 2015;43(3):206–21.

David A, Risitano DC, Mazzeo G, Sinardi L, Venuti FS, Sinardi AU. Central venous catheters and infections. Minerva Anesthesiol 2005;71(9):561–4.

Storey S, Brown J, Foley A, Newkirk E, Powers J, Barger J, et al. A comparative evaluation of antimicrobial coated versus nonantimicrobial coated peripherally inserted central catheters on associated outcomes: a randomized controlled trial. Am J Infect Control 2016;44(6):636–41.

Rosenthal VD, Maki DG, Mehta Y, Leblebicioglu H, Memish ZA, Al-Mousa HH, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 43 countries for 2007–2012. Device-associated module. Am J Infect Control 2014;42(9):942–56.

Olaechea PM, Palomar M, Alvarez-Lerma F, Otal JJ, Insausti J, Lopez-Pueyo MJ, et al. Morbidity and mortality associated with primary and catheter-related bloodstream infections in critically ill patients. Rev Esp Quimioter 2013;26(1):21–9.

Jamal MA, Rosenblatt JS, Hachem RY, Ying J, Pravinkumar E, Nates JL, et al. Prevention of biofilm colonization by Gram-negative bacteria on minocycline–rifampin-impregnated catheters sequentially coated with chlorhexidine. Antimicrob Agents Chemother 2014;58(2):1179–82.

Gilbert RE, Harden M. Effectiveness of impregnated central venous catheters for catheter related blood stream infection: a systematic review. Curr Opin Infect Dis 2008;21(3):235–45.

Wang H, Huang T, Jing J, Jin J, Wang P, Yang M, et al. Effectiveness of different central venous catheters for catheter-related infections: a network meta analysis. J Hosp Infect 2010;76(1):1–11.

Bodenham Chair A, Babu S, Bennett J, Binks R, Fee P, Fox B, et al. Association of Anaesthetists of Great Britain and Ireland: Safe vascular access 2016. Anaesthesia 2016;71(5):573–85.

Marena C, Zecca M, Carenini ML, Bruschi A, Bassi ML, Olivieri P, et al. Incidence of, and risk factors for, nosocomial infections among hematopoietic stem cell transplantation recipients, with impact on procedure-related mortality. Infect Control Hosp Epidemiol 2001;22(8):510–7.

Schuerer DJ, Zack JE, Thomas J, Borecki IB, Sona CS, Schallom ME, et al. Effect of chlorhexidine/silver sulfadiazine-impregnated central venous catheters in an intensive care unit with a low blood stream infection rate after implementation of an educational program: a before-after trial. Surg Infect (Larchmt) 2007;8(4):445–54.

McConnell SA, Gubbins PO, Anaissie EJ. Do antimicrobial-impregnated central venous catheters prevent catheter-related bloodstream infection? Clin Infect Dis 2003;37(1);65–72.

Bonne S, Mazuski JE, Sona C, Schallom M, Boyle W, Buchman TG, et al. Effectiveness of minocycline and rifampin vs chlorhexidine and silver sulfadiazineimpregnated central venous catheters in preventing central line-associated bloodstream infection in a high-volume academic intensive care unit: A before and after trial. J Am Coll Surg 2015;221(3):739–47.

Ostendorf T, Meinhold A, Harter C, Salwender H, Egerer G, Geiss HK, et al. Chlorhexidine and silversulfadiazine coated central venous catheters in haematological patients–a double-blind, randomised, prospective, controlled trial. Support Care Cancer 2005;13(2):993–1000.

Kramer RD, Rogers MA, Conte M, Mann J, Saint S, Chopra V. Are antimicrobial peripherally inserted central catheters associated with reduction in central line–associated bloodstream infection? A systematic review and meta-analysis. Am J Infect Control 2017;45(2):108–14.

Chen YM, Dai AP, Shi Y, Liu ZJ, Gong MF, Yin XB. Effectiveness of silver-impregnated central venous catheters for preventing catheter-related blood stream infections: a meta-analysis. Int J Infect Dis 2014;29:279–86.

Chong HY, Lai NM, Apisarnthanarak A, Chaiyakunapruk N. Comparative Efficacy of Antimicrobial Central Venous Catheters in Reducing Catheter-Related Bloodstream Infections in Adults: Abridged Cochrane Systematic Review and Network Meta-Analysis. Clin Infect Dis 2017;64(Suppl 2):131–40.

Knetsch ML, Koole LH. New strategies in the development of antimicrobial coatings: the example of increasing usage of silver and silver nanoparticles. Polymers 2011;3(1):340–66.

Timsit JF, Rupp M, Bouza E, Chopra V, Kärpänen T, Laupland K, et al. A state of the art review on optimal practices to prevent, recognize, and manage complications associated with intravascular devices in the critically ill. Intensive Care Med 2018;44(6):742–59.

Vafa Homann M, Johansson D, Wallen H, Sanchez J. Improved ex vivo blood compatibility of central venous catheter with noble metal alloy coating. J Biomed Mater Res B Appl Biomater 2016;104(7):1359–65.

Downloads

Published

2019-01-15

Most read articles by the same author(s)